EA023466B1 - Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака - Google Patents
Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака Download PDFInfo
- Publication number
- EA023466B1 EA023466B1 EA201100779A EA201100779A EA023466B1 EA 023466 B1 EA023466 B1 EA 023466B1 EA 201100779 A EA201100779 A EA 201100779A EA 201100779 A EA201100779 A EA 201100779A EA 023466 B1 EA023466 B1 EA 023466B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antagonist
- patient
- cxce1
- breast cancer
- stem cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Изобретение относится к способу определения наличия стволовых клеток злокачественной солидной опухоли у пациента с раком молочной железы, где способ включает определение экспрессии белка CXCR1 в образце ткани опухоли, взятом у пациента с раком молочной железы, где наличие белка CXCR1 в образце ткани указывает на наличие стволовых клеток злокачественной солидной опухоли в молочной железе.
Description
(57) Изобретение относится к способу определения наличия стволовых клеток злокачественной солидной опухоли у пациента с раком молочной железы, где способ включает определение экспрессии белка СХСК1 в образце ткани опухоли, взятом у пациента с раком молочной железы, где наличие белка СХСК.1 в образце ткани указывает на наличие стволовых клеток злокачественной солидной опухоли в молочной железе.
023466 Β1
Claims (14)
1. Способ определения наличия стволовых клеток злокачественной солидной опухоли у пациента с раком молочной железы, где способ включает определение экспрессии белка СХСВ1 в образце ткани опухоли, взятом у пациента с раком молочной железы, где наличие белка СХСВ1 в образце ткани указывает на наличие стволовых клеток злокачественной солидной опухоли в молочной железе.
- 61 023466
2. Способ по п.1, где указанная стадия определения включает приведение указанного образца ткани в контакт с антителом или фрагментом антитела.
3. Способ по п.1, где указанная стадия определения включает приведение указанного образца ткани в контакт с репертаксином.
4. Способ по п.2, где указанное антитело или фрагмент антитела конъюгированы с сигнальной молекулой.
5. Способ по п.4, где указанная сигнальная молекула представляет собой флуоресцирующую молекулу или фермент, который может катализировать цветную реакцию в присутствии колориметрического субстрата.
6. Способ лечения пациента с раком молочной железы, при котором опухоль содержит стволовые клетки, включающий введение антагониста СХСЕ1 или РВХО21 или антагониста пути передачи сигнала 1Ь-8/СХСЕ1 указанному пациенту.
7. Способ лечения пациента с раком молочной железы, включающий введение антагониста СХСЕ1 или РВХО21 или антагониста пути передачи сигнала 1Ь-8/СХСЕ1 в сочетании с химиотерапевтическим средством указанному пациенту.
8. Способ по п. 6 или 7, где указанный антагонист представляет собой репертаксин или его производное.
9. Способ по п.6 или 7, где антагонист состоит из антитела или фрагмента антитела.
10. Способ по любому из пп.1-5, при котором также определяют по меньшей мере один маркер, выбранный из СБ44, СБ24, Е8А, АЬВН, ТРЕХЪ, \ОТСН2, ЕВМ15, 8Т3ОАЬ3, ΝΡΥ^ РС\Х, О1РС3, КАВ51Ы, АЕГО1В.
11. Применение антагониста СХСЕ1 или антагониста пути передачи сигнала 1Ь-8/СХСЕ1 для лечения пациента с раком молочной железы, при котором опухоль содержит стволовые клетки.
12. Применение антагониста СХСЕ1 или антагониста пути передачи сигнала ГБ-8/СХСЕ1 в сочетании с химиотерапевтическим средством для лечения пациента с раком молочной железы.
13. Применение по п.11 или 12, где указанный антагонист представляет собой репертаксин или его производное.
14. Применение по п.11 или 12, где указанный антагонист состоит из антитела или фрагмента антитела.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11345808P | 2008-11-11 | 2008-11-11 | |
| PCT/US2009/064041 WO2010056753A1 (en) | 2008-11-11 | 2009-11-11 | Anti-cxcr1 compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201100779A1 EA201100779A1 (ru) | 2011-12-30 |
| EA023466B1 true EA023466B1 (ru) | 2016-06-30 |
Family
ID=42170302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201100779A EA023466B1 (ru) | 2008-11-11 | 2009-11-11 | Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8940301B2 (ru) |
| EP (2) | EP3153862A1 (ru) |
| JP (3) | JP5716180B2 (ru) |
| KR (3) | KR20110093893A (ru) |
| CN (3) | CN102272599B (ru) |
| AU (1) | AU2009314141B2 (ru) |
| BR (1) | BRPI0921150B1 (ru) |
| CA (1) | CA2743305C (ru) |
| CY (1) | CY1118933T1 (ru) |
| DK (1) | DK2356462T3 (ru) |
| EA (1) | EA023466B1 (ru) |
| ES (1) | ES2623128T3 (ru) |
| HK (3) | HK1161350A1 (ru) |
| HR (1) | HRP20170463T1 (ru) |
| HU (1) | HUE032623T2 (ru) |
| IL (1) | IL212822A (ru) |
| LT (1) | LT2356462T (ru) |
| MX (2) | MX2011005007A (ru) |
| NZ (2) | NZ625440A (ru) |
| PL (1) | PL2356462T3 (ru) |
| PT (1) | PT2356462T (ru) |
| RS (1) | RS55784B1 (ru) |
| SG (1) | SG10201701954QA (ru) |
| SI (1) | SI2356462T1 (ru) |
| WO (1) | WO2010056753A1 (ru) |
| ZA (1) | ZA201103416B (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
| RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272599B (zh) | 2008-11-11 | 2015-01-14 | 密执安大学评议会 | 抗cxcr1组合物和方法 |
| GB201106870D0 (en) * | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| WO2013067055A1 (en) * | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| CN103159650B (zh) * | 2011-12-19 | 2016-04-20 | 天津市国际生物医药联合研究院 | 芳香杂环磺酰胺类化合物的制备及其应用 |
| CN103159649B (zh) * | 2011-12-19 | 2016-03-09 | 天津市国际生物医药联合研究院 | 磺酰胺类化合物的制备及其应用 |
| EP2831112A1 (en) * | 2012-03-29 | 2015-02-04 | Friedrich Miescher Institute for Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
| ES2728305T3 (es) * | 2013-04-29 | 2019-10-23 | Ogd2 Pharma | Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas |
| JP6683986B2 (ja) * | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
| EP3518898A4 (en) | 2016-10-03 | 2020-06-17 | The Children's Medical Center Corporation | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY |
| CN110168646B (zh) * | 2016-11-17 | 2023-12-19 | 南特生物科学公司 | 预测抗癌途径的验证 |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US10980739B2 (en) | 2016-12-14 | 2021-04-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US10100275B2 (en) | 2017-03-16 | 2018-10-16 | King Faisal Specialist Hospital & Research Centre | Method for generating human multipotent mammary stem cells from normal primary breast luminal cells |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3854411A1 (en) * | 2020-01-10 | 2021-07-28 | Rise Biopharmaceuticals, Inc. (Beijing) | Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy |
| CN114075286A (zh) * | 2020-08-21 | 2022-02-22 | 张家港博泽利斯生物技术有限公司 | 一种抗人cxcr1蛋白单克隆抗体的制备方法 |
| JPWO2023032957A1 (ru) * | 2021-08-30 | 2023-03-09 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070208074A1 (en) * | 2006-01-24 | 2007-09-06 | Bonni Azad M | Methods and compositions for treating and preventing tumors |
| US20080187938A1 (en) * | 2006-09-22 | 2008-08-07 | The Regents Of The University Of Michigan | ALDH1 As A Cancer Stem Cell Marker |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
| US4323546A (en) | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4981785A (en) | 1988-06-06 | 1991-01-01 | Ventrex Laboratories, Inc. | Apparatus and method for performing immunoassays |
| US4968103A (en) | 1988-07-22 | 1990-11-06 | Photofinish Cosmetics Inc. | Method of making a brush |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| US5376313A (en) | 1992-03-27 | 1994-12-27 | Abbott Laboratories | Injection molding a plastic assay cuvette having low birefringence |
| JP3537141B2 (ja) | 1992-10-30 | 2004-06-14 | ザ ゼネラル ホスピタル コーポレーション | 新種蛋白質分離のための相互作用を用いる補捉システム |
| US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5876978A (en) | 1993-04-06 | 1999-03-02 | Medical College Of Ohio | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5643765A (en) | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5599677A (en) | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6156305A (en) | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP2000512126A (ja) * | 1995-11-16 | 2000-09-19 | ダーム、ミヒャエル・ヴェー | 体液中の腫瘍細胞を数量化するための方法およびかかる方法に適合した試験キット |
| JP2000502450A (ja) | 1995-12-22 | 2000-02-29 | アボツト・ラボラトリーズ | 蛍光偏光免疫アッセイによる診断法 |
| US5885529A (en) | 1996-06-28 | 1999-03-23 | Dpc Cirrus, Inc. | Automated immunoassay analyzer |
| KR20000049096A (ko) | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
| ATE363652T1 (de) | 1997-03-07 | 2007-06-15 | Clare Chemical Res Inc | Fluorometrischer nachweis mit sichtbarem light |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| WO2003050502A2 (en) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| US20020147312A1 (en) * | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
| AU2003291549A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| CN101090729B (zh) * | 2003-05-30 | 2014-07-23 | 艾更斯司股份有限公司 | 前列腺干细胞抗原(psca)变体及其序列 |
| EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20050142136A1 (en) * | 2003-10-23 | 2005-06-30 | Lary Suva | Anti-interleukin 8 therapy for tumor osteolysis |
| WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| WO2005103711A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1) |
| MXPA06013118A (es) | 2004-05-12 | 2007-02-28 | Schering Corp | Antagonistas de cxcr1 y cxcr2 de quimocina. |
| GB0417740D0 (en) | 2004-08-10 | 2004-09-08 | Uc3 | Methods and kit for the prognosis of breast cancer |
| JP5129149B2 (ja) * | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
| TWI414517B (zh) * | 2006-04-21 | 2013-11-11 | Smithkline Beecham Corp | Ｉｌ-８受體拮抗劑 |
| JP5311439B2 (ja) * | 2006-12-27 | 2013-10-09 | 日本メナード化粧品株式会社 | 皮膚の状態を評価する方法及びその用途 |
| CN101126758A (zh) * | 2007-09-06 | 2008-02-20 | 江苏省肿瘤医院 | 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法 |
| WO2010009121A2 (en) * | 2008-07-15 | 2010-01-21 | University Of Florida Research Foundation, Inc. | Colon stem cells associated with colitis and colorectal cancer and methods of use |
| CN102272599B (zh) | 2008-11-11 | 2015-01-14 | 密执安大学评议会 | 抗cxcr1组合物和方法 |
-
2009
- 2009-11-11 CN CN200980153571.6A patent/CN102272599B/zh active Active
- 2009-11-11 NZ NZ625440A patent/NZ625440A/en unknown
- 2009-11-11 PT PT98266760T patent/PT2356462T/pt unknown
- 2009-11-11 LT LTEP09826676.0T patent/LT2356462T/lt unknown
- 2009-11-11 SI SI200931627A patent/SI2356462T1/sl unknown
- 2009-11-11 WO PCT/US2009/064041 patent/WO2010056753A1/en active Application Filing
- 2009-11-11 BR BRPI0921150-0A patent/BRPI0921150B1/pt active IP Right Grant
- 2009-11-11 PL PL09826676T patent/PL2356462T3/pl unknown
- 2009-11-11 DK DK09826676.0T patent/DK2356462T3/en active
- 2009-11-11 EP EP16200083.0A patent/EP3153862A1/en not_active Withdrawn
- 2009-11-11 CN CN201410775973.2A patent/CN104623664B/zh active Active
- 2009-11-11 MX MX2011005007A patent/MX2011005007A/es active IP Right Grant
- 2009-11-11 NZ NZ602369A patent/NZ602369A/en unknown
- 2009-11-11 US US12/616,579 patent/US8940301B2/en active Active
- 2009-11-11 SG SG10201701954QA patent/SG10201701954QA/en unknown
- 2009-11-11 HU HUE09826676A patent/HUE032623T2/hu unknown
- 2009-11-11 CA CA2743305A patent/CA2743305C/en active Active
- 2009-11-11 EP EP09826676.0A patent/EP2356462B1/en active Active
- 2009-11-11 EA EA201100779A patent/EA023466B1/ru unknown
- 2009-11-11 CN CN201410775991.0A patent/CN104634972B/zh active Active
- 2009-11-11 AU AU2009314141A patent/AU2009314141B2/en active Active
- 2009-11-11 KR KR1020117013420A patent/KR20110093893A/ko active Application Filing
- 2009-11-11 RS RS20170301A patent/RS55784B1/sr unknown
- 2009-11-11 ES ES09826676.0T patent/ES2623128T3/es active Active
- 2009-11-11 KR KR1020147028842A patent/KR101588547B1/ko active IP Right Grant
- 2009-11-11 KR KR1020157013977A patent/KR20150065930A/ko active IP Right Grant
- 2009-11-11 JP JP2011535789A patent/JP5716180B2/ja active Active
-
2011
- 2011-05-10 ZA ZA2011/03416A patent/ZA201103416B/en unknown
- 2011-05-11 IL IL212822A patent/IL212822A/en active IP Right Grant
- 2011-05-11 MX MX2015011045A patent/MX351889B/es unknown
-
2012
- 2012-02-24 HK HK12101909.4A patent/HK1161350A1/xx unknown
- 2012-02-24 HK HK15106856.3A patent/HK1206256A1/xx unknown
-
2013
- 2013-10-11 JP JP2013214161A patent/JP5909783B2/ja active Active
-
2014
- 2014-12-10 US US14/566,436 patent/US10557850B2/en active Active
- 2014-12-10 US US14/566,415 patent/US9606124B2/en active Active
-
2015
- 2015-07-20 HK HK15106853.6A patent/HK1206421A1/xx unknown
- 2015-11-16 JP JP2015223818A patent/JP2016065082A/ja not_active Withdrawn
-
2017
- 2017-03-21 HR HRP20170463TT patent/HRP20170463T1/hr unknown
- 2017-03-29 CY CY20171100385T patent/CY1118933T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070208074A1 (en) * | 2006-01-24 | 2007-09-06 | Bonni Azad M | Methods and compositions for treating and preventing tumors |
| US20080187938A1 (en) * | 2006-09-22 | 2008-08-07 | The Regents Of The University Of Michigan | ALDH1 As A Cancer Stem Cell Marker |
Non-Patent Citations (1)
| Title |
|---|
| SOUZA et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury Br J Pharmacol 2004, vol 143(1), p 132-142 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
| RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023466B1 (ru) | Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака | |
| Hamson et al. | Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy | |
| Delongchamps et al. | Evaluation of prostatitis in autopsied prostates—is chronic inflammation more associated with benign prostatic hyperplasia or cancer? | |
| Patel et al. | Clinical significance of MMP‐2 and MMP‐9 in patients with oral cancer | |
| Ishii et al. | Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion | |
| Chung et al. | A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer | |
| Samoszuk et al. | Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts | |
| Repetto et al. | Levels of soluble E‐cadherin in breast, gastric, and colorectal cancers | |
| Giannelli et al. | Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications | |
| Betsunoh et al. | Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma | |
| ATE490465T1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| Arima et al. | Nuclear translocation of ADAM‐10 contributes to the pathogenesis and progression of human prostate cancer | |
| Cashman et al. | SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade | |
| AU2010291710B2 (en) | Methods and compositions for detection of lethal cell and uses thereof | |
| Song et al. | Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels | |
| Bădescu et al. | Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer | |
| Sun et al. | Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer | |
| WO2009019367A3 (fr) | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal | |
| WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
| JP2017158562A (ja) | 患者における癌の診断方法 | |
| TW200700089A (en) | Recombinant protein comprising starch binding domain and use thereof | |
| Bosse et al. | Mass spectrometry‐based secretome analysis of non‐small cell lung cancer cell lines | |
| Do et al. | Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck | |
| Attaran et al. | Peroxiredoxin-1 Tyr194 phosphorylation regulates LOX-dependent extracellular matrix remodelling in breast cancer | |
| WO2009019369A3 (fr) | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal |